Kilter Group’s Biogen BIIB Stock Holding History

Kilter Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.53K	Buy	52 +3	+6%	+$553	﹤0.01%	421
2025 Q4	$8.62K	Buy	49 +14	+40%	+$2.29K	﹤0.01%	391
2025 Q3	$4.9K	Buy	35 +15	+75%	+$2.03K	﹤0.01%	465
2025 Q2	$2.51K	Buy	+20	New	+$2.49K	﹤0.01%	555

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kilter Group's BIIB Position: Q1 2026 in Review

Kilter Group increased its Biogen (BIIB) stake by 6.1% in Q1 2026, buying an estimated $553 and bringing the position to 52 shares worth $9.53K. The position accounts for ﹤0.01% of the portfolio, ranked #421.

Kilter Group first reported a position in BIIB in Q2 2025 and has held it in 4 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Kilter Group held 52 shares of Biogen worth $9.53K as of Q1 2026.
Kilter Group bought 3 Biogen shares in Q1 2026, an estimated $553.
Biogen made up ﹤0.01% of Kilter Group's portfolio in Q1 2026, its #421 holding.
Kilter Group first reported a position in Biogen in Q2 2025 and has held it in 4 quarters since.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Kilter Group's 13F filing for Q1 2026, filed 14 May 2026.